Page 1

zentalis Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update August 12 , 2021 Reported promising new interim data on both ZN - c3 and ZN - c5 , highlighting their potentially best - in - class profiles Dosed the first patient in a potentially registrational Phase 2 trial of ZN - c3 in patients with uterine serous carcinoma ( USC ) Raised approximately $ 173 million in gross proceeds from recent follow - on offering NEW YORK and SAN DIEGO , Aug. 12 , 2021 ( GLOBE NEWSWIRE ) -- Zentalis Pharmaceuticals , Inc. ( Nasdaq : ZNTL ) , a clinical - stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers , today announced financial results for the second quarter ended June 30 , 2021 and highlighted recent corporate accomplishments . " We have had an extremely productive second quarter , marked by significant clinical and regulatory advances that were outlined in our mid - year review in June . The data presented continue to support our candidates ' potential for best - in - class positioning - both as monotherapies and in combinations - for an array of difficult - to - treat cancers , " commented Dr. Anthony Sun , Chairman and Chief Executive Officer of Zentalis . " Of note , our lead candidate , ZN - c3 , demonstrated additional deepening and durable tumor responses , and based on this maturing data presented in June , we have identified potential accelerated approval paths for this candidate in USC and a biomarker - driven setting , with the Phase 2 trial in USC already underway . " Continued Dr. Sun , " Furthermore , this momentous period for Zentalis was reinforced by the completion of a recent upsized public offering in which we raised approximately $ 173 million in gross proceeds . This financing ensures we are well - positioned to fund all upcoming key milestones , with the goal of delivering differentiated cancer treatments to patients globally . " Program Highlights : • In June 2021 , Zentalis hosted a mid - year update webcast , providing key clinical and regulatory updates across its pipeline . Clinical highlights from the update included : five confirmed Partial Responses ( PRs ) and one unconfirmed PR in the Phase 1 monotherapy trial of ZN - c3 in a range of heavily pre - treated solid tumors ; plans for two potentially registrational trials for ZN - c3 in USC and a biomarker - driven setting ; an oral dose of 50 mg QD demonstrating a Clinical Benefit Rate of 40 % in the Phase 1 monotherapy trial of ZN - c5 in ER + / HER2- breast cancer . For more information on the clinical results reported , click here . • In July 2021 , the Company dosed the first patient in a Phase 2 trial of ZN - c3 in women with recurrent or persistent USC . Following an end - of - Phase 1 meeting , the U.S. Food and Drug Administration ( FDA ) agreed in principle that ZN - c3 has the potential for an accelerated approval pathway based on the Phase 2 global study design in USC . • In June 2021 , the Company received orphan drug and rare pediatric disease designations from the FDA for ZN - c3 in combination with chemotherapy for the treatment of osteosarcoma . Zentalis expects to initiate a Phase 1/2 trial in 3Q 2021 . • In April 2021 , Zentalis reported initial results from the Phase 1 portion of a Phase 1/2 trial of ZN - c3 in advanced solid tumors in a late - breaking session at the AACR Annual Meeting , which was further discussed at a webcast event with Key Opinion Leaders . • In April 2021 , Zentalis entered into a Clinical Trial Collaboration and Supply Agreement with GSK to investigate the combination of ZN - c3 and niraparib , GSK's poly ( ADP - ribose ) polymerase ( PARP ) inhibitor , in patients with advanced epithelial ovarian cancer . The Company expects to initiate a Phase 1b trial with this combination in the second half of 2021 . Zentera Highlights : • In July 2021 , Zentera , a Shanghai - based clinical - stage biopharmaceutical company formed by Zentalis , announced the completion of a $ 75 million Series B financing . The proceeds will be used to advance the clinical development of three Zentalis - discovered candidates , ZN - c3 , ZN - c5 and ZN - d5 , in China , in addition to business development opportunities for pipeline expansion . • As of July 2021 , Zentera had received CTA acceptances in China for ZN - c3 , ZN - c3 in combination , ZN - c5 and ZN - d5 . Two